Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
- 15 June 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 21 (7), 957-968
- https://doi.org/10.1016/s1470-2045(20)30180-7
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
- Dana-Farber/Harvard Cancer Center
- National Institutes of Health (UM1 CA186709)
This publication has 29 references indexed in Scilit:
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATRNature Chemical Biology, 2011
- ATR: a master conductor of cellular responses to DNA replication stressTrends in Biochemical Sciences, 2011
- The involvement of FANCM, FANCI, and checkpoint proteins in the interstrand DNA crosslink repair pathway is conserved in C. elegansDNA Repair, 2010
- Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian CancerJournal of Clinical Oncology, 2008
- Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian CancerJournal of Clinical Oncology, 2007
- Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell SurvivalMolecular Pharmacology, 2005
- Activation of the DNA damage checkpoint and genomic instability in human precancerous lesionsNature, 2005
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994